Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Soriot Stands By His Post-Pfizer Sales Pledge For AstraZeneca

Executive Summary

Pascal Soriot stands by the ambitious growth target he set for AstraZeneca in his defense against Pfizer's 2014 bid for the company. Any shortfall in the target of $45bn by 2023 will reflect the weakening of the dollar rather than product challenges for the UK company, the bullish CEO told Scrip one day after the company delivered disappointing Phase III data that slashed around 15% from its share price.

You may also be interested in...



Pharma Q3 Results Preview: Pfizer, Allergan, Sanofi, Teva & AstraZeneca

Pfizer’s CEO will likely shed more light on the company’s on-off-on attitude towards its consumer health business, while Allergan will certainly have a lot of explaining to do regarding its Restasis patent protection strategy. Sanofi, Teva and AstraZeneca are also scheduled to report Q3 results in the coming days. Scrip outlines the key issues to watch for.

Teva SOS: Troubled Drug Maker Seeks Audacious Captain To Take The Wheel

Teva investors have moved beyond restless to the point of jumping ship as the company's generic drug business continues to underperform, with little guidance on plans for a turnaround.

Teva SOS: Troubled Drug Maker Seeks Audacious Captain To Take The Wheel

Teva investors have moved beyond restless to the point of jumping ship as the company's generic drug business continues to underperform, with little guidance on plans for a turnaround.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099227

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel